Comparison of thrice-daily lispro 50/50 vs thrice-daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetes

Journal of Diabetes Investigation

Volumn 1, Issue 4, 2010, Pages 149-153

  Yamashiro, Keiko ^a   Ikeda, Fuki ^a   Fujitani, Yoshio ^a   Watada, Hirotaka ^a   Kawamori, Ryuzo ^a   Hirose, Takahisa ^a  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hypoglycemia; Insulin lispro; Mid mix insulin

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN LISPRO; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PARALLEL DESIGN; PRIORITY JOURNAL;

EID: 79953762327     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2010.00025.x     Document Type: Article

References (20)

1. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-1972.
2. International Diabetes Federation, Clinical Guidelines Task Force. Global guideline for type 2 diabetes. International Diabetes Federation, Brussels, Belgium. 2005.
3. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
4. Yki-Järvinnen H, Dressler A, Ziemen M; the HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better postdinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000; 23: 1130- 1136.
5. Yki-Järvinnen H. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2002; 18: S77-S81.
6. Riddle MC, Rosenstock J, Gerich J; the Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26; 2003:3080-3086.
7. Rosenstock J. Basal insulin suppslementation in type 2 diabetes: refining the tactics. Am J Med 2004; 116: 10S-16S.
8. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-näi{dotless}ve people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274.
9. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716-1730.
10. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008; 31: 173- 175.
11. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17-30.
12. Kazda C, Hulstrunk H, Helsberg K, et al. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications 2006; 20: 145-152.
13. Jacober SJ, Scism-Bacon JL, Zagar AJ; for the IONW Study Investigator. A comparison of intensive mixture therapy with basal insulin therapy in insulin-näi{dotless}ve patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab 2006; 8: 448-455.
14. Ilag LL, Kerr L, Malone JK, Tan MH. Prandial premixed insulin analogue regimens versus basal insulin analogue regimen in the management o type 2 diabetes: an evidence-based comparison. Clin Ther 2007; 29: 1254-1270.
15. Robbins DC, Beisswenger PJ, Ceriello A, et al. Mealtime 50/50 basal + prandial analogue mixture with a basal insulin analogue, both plus metformin, in blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther 2007; 29: 2349-2364.
16. Ebato C, Shimizu T, Arakawa M, et al. Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): Comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride. Diabetes Res Clin Pract 2009; 86: 31-36.
17. Rosenstock J, Scism-Bacon J, Ahmann AJ, et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents. Prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008; 31: 20-25.
18. Holman RR, Farmer AF, Davies MJ, et al. for the 4T study group. Three-year efficacy of complex insulin regimen in type 2 diabetes. N Engl J Med ORG 2009; 361: 1736-1747.
19. Yokoyama H, Tada J, Kamikawa F, et al. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Res Clin Pract 2006; 73: 35-40.
20. Tamaki M, Shimizu T, Kanazawa A, et al. Effect of changes in basal/total daily insulin ratio in type 2 diabetes patients on intensive insulin therapy including insulin glargine (JUN-LAN Study 6). Diabetes Res Clin Pract 2008, doi:10.1016/j.diabres. 2008.03.021.